Influenza activity in the United States was low during October 2018, and, although it increased slowly during November, activity remains low across most of the country.* During the week ending December 1, 2018, the percentage of outpatient visits for influenza-like illness † (ILI) was equal to the national baseline § (Figure) and was at or slightly above the region-specific baseline in four of the 10 U.S. Department of Health and Human Services regions ¶ (Regions 4 and 7-9). The majority of jurisdictions experienced minimal or low ILI activity since September 30; however, two experienced moderate ILI activity, and two experienced high ILI activity** during the week ending December 1. The percentage of deaths attributed to pneumonia and influenza remains below the epidemic threshold, † † and the rate of influenza-associated hospitalizations remains low. Five laboratory-confirmed, Region 10: Alaska, Idaho, Oregon, and Washington. ** Activity levels are based on the percentage of outpatient visits in a jurisdiction attributed to ILI and are compared with the average percentage of ILI visits that occur during weeks with little or no influenza virus circulation. Activity levels range from minimal, corresponding to ILI activity from outpatient clinics at or below the average, to high, corresponding to ILI activity from outpatient clinics much higher than the average. Because the clinical definition of ILI is nonspecific, not all ILI is caused by influenza; however, when combined with laboratory data, the information on ILI activity provides a clearer picture of influenza activity in the United States. † † The seasonal baseline proportion of pneumonia and influenza deaths is projected using a robust regression procedure, in which a periodic regression model is applied to the observed percentage of deaths from pneumonia and influenza that were reported by the National Center for Health Statistics Mortality Surveillance System during the preceding 5 years. The epidemic threshold is set at 1.645 standard deviations above the seasonal baseline. The timing of influenza activity often varies; however, influenza activity will increase in coming weeks and is likely to peak during December-February. Annual influenza vaccination is recommended for all persons aged ≥6 months who do not have contraindications (1) . Multiple influenza vaccines are approved and recommended for use during the 2018-19 season, and vaccination should continue to be offered as long as influenza viruses are circulating and unexpired vaccine is available. For the 2018-19 season, manufacturers projected they would supply the United States with 163-168 million doses § § Levels of activity are 1) no activity; 2) sporadic: isolated laboratory-confirmed influenza cases or a laboratory-confirmed outbreak in one institution, with no increase in activity; 3) local: increased ILI or two or more institutional outbreaks (ILI or laboratory-confirmed influenza) in one region of the state, with recent laboratory evidence of influenza in that region; virus activity no greater than sporadic in other regions; 4) regional: increased ILI activity or institutional outbreaks (ILI or laboratory-confirmed influenza) in two or more outbreaks, but less than half of the regions in the state with recent laboratory evidence of influenza in those regions; and 5) widespread: increased ILI activity or institutional outbreaks (ILI or laboratory-confirmed influenza) in at least half the regions in the state, with recent laboratory evidence of influenza in the state. During the week ending December 1, 2018, nine states (California, Connecticut, Georgia, Kentucky, Louisiana, Nevada, New York, Oregon, and Vermont) reported regional activity, and one state (Massachusetts) reported widespread activity. There are four recommended influenza antiviral medications for treatment of influenza this season: oral oseltamivir, inhaled zanamivir, intravenous peramivir, and the newly approved oral baloxavir. Treatment with influenza antiviral medications as close to the onset of illness as possible is recommended for patients with confirmed or suspected influenza who have severe, complicated, or progressive illness; who require hospitalization; or who are at high risk for influenza complications. Some antiviral medications (oseltamivir and zanamivir) can be considered for chemoprophylaxis to prevent influenza in certain situations; however, general seasonal or preexposure antiviral chemoprophylaxis is not recommended. Updated recommendations for use of antiviral drugs are available (https://www.cdc.gov/flu/professionals/antivirals/summaryclinicians.htm).
Influenza surveillance reports for the United States are posted online weekly (https://www.cdc.gov/flu/weekly). Additional information regarding influenza viruses, influenza surveillance, influenza vaccines, and influenza antiviral medications is available online (https://www.cdc.gov/flu).
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